ASH 2018 | CLL news from ASH 2018: ibrutinib strikes again!

VJHemOnc is committed to improving our service to you

Stephan Stilgenbauer

Stephan Stilgenbauer, MD, of the University of Ulm, Ulm, Germany, discusses the chronic lymphocytic leukemia (CLL) highlights at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Share this video  
Similar topics
Related videos
5:17
COVID-19: treating CLL patients
Constantine Tam
4:07
Horizon scan: CLL and CAR-T
Constantine Tam
4:10
Primary and secondary plasma cell leukemia
Artur Jurczyszyn
5:09
A CAR-T round-up with Arnon Nagler
Arnon Nagler
2:06
Polish experience of COVID-19
Artur Jurczyszyn
Chronic Lymphocytic Leukemia, Leukemia
Bendamustine, Ibrutinib, Obinutuzumab, Rituximab, Venetoclax
ALLIANCE A041202, ECOG-E1912, iLLUMINATE, MURANO
ASH 2018, ASH2018CLL
Interview
More from Stephan Stilgenbauer
Still a role for chemoimmunotherapy in CLL: GREEN results
Can we afford to have CLL patients on a therapy for the rest of their lives?
Phase II trial of venetoclax monotherapy for relapsed/refractory CLL with 17p deletion
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals